McGaughey Georgia, Bayly Christopher I, Cox Christopher D, Schreier John D, Breslin Michael J, Bogusky Michael, Pitzenberger Steve, Ball Richard, Coleman Paul J
Chemistry, Modeling and Informatics, Merck Research Laboratories, WP53F-301, West Point, PA, 19486, USA,
J Comput Aided Mol Des. 2014 Jan;28(1):5-12. doi: 10.1007/s10822-014-9710-x. Epub 2014 Feb 1.
Dual Orexin Receptor Antagonists (DORA) bind to both the Orexin 1 and 2 receptors. High resolution crystal structures of the Orexin 1 and 2 receptors, both class A GPCRs, were not available at the time of this study, and thus, ligand-based analyses were invoked and successfully applied to the design of DORAs. Computational analysis, ligand based superposition, unbound small-molecule X-ray crystal structures and NMR analysis were utilized to understand the conformational preferences of key DORAs and excellent agreement between these orthogonal approaches was seen in the majority of compounds examined. The predominantly face-to-face (F2F) interaction observed between the distal aromatic rings was the core 3D shape motif in our design principle and was used in the development of compounds. A notable exception, however, was seen between computation and experiment for suvorexant where the molecule exhibits an extended conformation in the unbound small-molecule X-ray structure. Even taking into account solvation effects explicitly in our calculations, we nevertheless find support that the F2F conformation is the bioactive conformation. Using a dominant states approximation for the partition function, we made a comprehensive assessment of the free energies required to adopt both an extended and a F2F conformation of a number of DORAs. Interestingly, we find that only a F2F conformation is consistent with the activities reported.
双重食欲素受体拮抗剂(DORA)可与食欲素1型和2型受体结合。在本研究开展时,作为A类G蛋白偶联受体(GPCR)的食欲素1型和2型受体的高分辨率晶体结构尚未获得,因此,基于配体的分析方法被采用并成功应用于DORA的设计。利用计算分析、基于配体的叠加、未结合小分子的X射线晶体结构以及核磁共振分析来了解关键DORA的构象偏好,并且在大多数所研究的化合物中,这些正交方法之间呈现出高度一致性。在我们的设计原则中,远端芳香环之间主要观察到的面对面(F2F)相互作用是核心三维形状基序,并被用于化合物的研发。然而,在针对苏沃雷生的计算和实验之间存在一个显著例外,该分子在未结合小分子的X射线结构中呈现出伸展构象。即使在我们的计算中明确考虑了溶剂化效应,但我们仍然发现有证据支持F2F构象是生物活性构象。使用配分函数的主导态近似方法,我们对多种DORA采取伸展构象和F2F构象所需的自由能进行了全面评估。有趣的是,我们发现只有F2F构象与所报道的活性一致。